EMA starts evaluation of Moderna's booster application

Moderna has applied for the European health authority's approval for the use of its Covid-19 vaccine, Spikevax, as a booster dose in re-vaccination schemes.
Photo: David W Cerny/Reuters/Ritzau Scanpix
Photo: David W Cerny/Reuters/Ritzau Scanpix

The European Medicines Agency (EMA) has begun its assessment of data from US-based Moderna, which has applied for the approval of its Spikevax in use as a Covid-19 booster vaccine, the EMA reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading